Ability to Drive of Early Stage Alzheimer Disease (DRIVE COG)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2012 by CHU de Reims.
Recruitment status was  Not yet recruiting
Sponsor:
Information provided by (Responsible Party):
CHU de Reims
ClinicalTrials.gov Identifier:
NCT01566071
First received: March 27, 2012
Last updated: March 28, 2012
Last verified: March 2012
  Purpose

The main objectives of this study are:

  • To evaluate the driving capacities in a population of elderly subjects with early stage Alzheimer Disease (AD) in a real-life situation.
  • Define a typology of the main errors made in this population.
  • Propose adaptive measures or technological aids that would make it possible for these patients to maintain their ability to drive a car while limiting risk.

Condition Intervention
Alzheimer Disease
Other: Assessment of drive abilities

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Primary Purpose: Diagnostic

Resource links provided by NLM:


Further study details as provided by CHU de Reims:

Estimated Enrollment: 60
  Eligibility

Ages Eligible for Study:   70 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

The following subjects will be included and classified as " patients " :

  • Age > 70 years
  • With established diagnosis of Alzheimer's disease as defined by DSM IV
  • With MMSE score ≥ 24 (early-stage Alzheimer's disease)
  • Holder of a valid driving license
  • With regular driving activity (drives at least once per week)
  • Informed consent provided.

The following subjects will be included and classified as " controls " :

  • Age > 70 years,
  • Absence of cognitive impaired that interferes with their daily life at initial evaluation,
  • Holder of a valid driving license,
  • With regular driving activity (drives at least once per week),
  • Informed consent provided.

Exclusion Criteria:

  • Dementia syndrome(s) other than Alzheimer's disease,
  • MMSE score < 24
  • Informed consent not provide
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01566071

Contacts
Contact: Jean-Luc NOVELLA jlnovella@chu-reims.fr

Locations
France
CHU de REIMS Not yet recruiting
Reims, France, 51092
Contact: Jean-Luc NOVELLA, MD PhD       jlnovella@chu-reims.fr   
Principal Investigator: Jean-Luc NOVELLA, MD PhD         
Sponsors and Collaborators
CHU de Reims
Investigators
Principal Investigator: JEAN-LUC NOVELLA, MD PhD CHU de Reims
  More Information

No publications provided

Responsible Party: CHU de Reims
ClinicalTrials.gov Identifier: NCT01566071     History of Changes
Other Study ID Numbers: REIMS-PHRCNAT2011-N11-02
Study First Received: March 27, 2012
Last Updated: March 28, 2012
Health Authority: France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)

Additional relevant MeSH terms:
Alzheimer Disease
Dementia
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Tauopathies
Neurodegenerative Diseases
Delirium, Dementia, Amnestic, Cognitive Disorders
Mental Disorders

ClinicalTrials.gov processed this record on September 30, 2014